Data di Pubblicazione:
2022
Abstract:
Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for diffuse large B-cell lymphoma after at least two treatment lines.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Progression-Free Survival; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Salvage Therapy; Transplantation, Autologous; Hematopoietic Stem Cell Transplantation; Immunotherapy, Adoptive
Elenco autori:
Bishop, Michael R; Dickinson, Michael; Purtill, Duncan; Barba, Pere; Santoro, Armando; Hamad, Nada; Kato, Koji; Sureda, Anna; Greil, Richard; Thieblemont, Catherine; Morschhauser, Franck; Janz, Martin; Flinn, Ian; Rabitsch, Werner; Kwong, Yok-Lam; Kersten, Marie J; Minnema, Monique C; Holte, Harald; Chan, Esther H L; Martinez-Lopez, Joaquin; Müller, Antonia M S; Maziarz, Richard T; Mcguirk, Joseph P; Bachy, Emmanuel; Le Gouill, Steven; Dreyling, Martin; Harigae, Hideo; Bond, David; Andreadis, Charalambos; Mcsweeney, Peter; Kharfan-Dabaja, Mohamed; Newsome, Simon; Degtyarev, Evgeny; Awasthi, Rakesh; Del Corral, Christopher; Andreola, Giovanna; Masood, Aisha; Schuster, Stephen J; Jäger, Ulrich; Borchmann, Peter; Westin, Jason R
Link alla scheda completa:
Link al Full Text:
Pubblicato in: